HELIOSON

Shanghai Helioson Pharmaceutical Co., Ltd. was founded in October 2021 and was located in Wisdom Plaza of Pujiang Town, Minhang District, Shanghai, with a registered capital of 88 million yuan. As a patient-oriented and clinical-value guided company, Helioson is mainly engaged in the therapeutic areas including hematoma and solid tumor based on the in-deep research and investigation of disease mechanism. Bulit with internationalization and differentiation mindset, we aim to develop innovative fist-in-class or best-in-class chemical drugs with great commercial value in global marketing.

88Million

Registered capital
2021Year Oct.

Date of establishment

Focus area

Tumor and autoimmune disease seriously endanger human health. Our primary mission is to develop novel and highly-effective drugs to satisfy the unmet medical needs of patients.

Technology platforms

To ensure that our goal is thoroughly and smoothly achieved, we have designed and established the protein homeostasis technology and computer aided drug design (CADD) platform, which facilitate the validation of protein targets that are highly related to the progression and recurrence of diseases, and eventually accelerate the discovery of new drug molecules.

The latest information